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The pre–B cell receptor promotes differentia-
tion and proliferation signals in B cell precursor 
cells within the bone marrow (Rolink et al., 
2000). It consists of an Ig  heavy chain ( chain; 
IGHM) coupled to the surrogate light chain with 
its two components, VpreB (VPREB1) and 5 
(IGLL1), which promote constitutive pre–B cell 
receptor signaling (van Loo et al., 2007; Fig. S1). 
Productive rearrangement of Ig VH to DJH gene 
segments is a prerequisite for the expression of 
a functional  chain, which is linked to the Ig 
and Ig transmembrane signaling chains (Guo 
et al., 2000). The key components of the prox-
imal pre–B cell receptor signaling cascade are 
assembled and stabilized by the linker protein 
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B cell lineage acute lymphoblastic leukemia (ALL) arises in virtually all cases from B cell 
precursors that are arrested at pre–B cell receptor–dependent stages. The Philadelphia 
chromosome–positive (Ph+) subtype of ALL accounts for 25–30% of cases of adult ALL, has 
the most unfavorable clinical outcome among all ALL subtypes and is defined by the onco-
genic BCR-ABL1 kinase and deletions of the IKAROS gene in >80% of cases. Here, we 
demonstrate that the pre–B cell receptor functions as a tumor suppressor upstream of 
IKAROS through induction of cell cycle arrest in Ph+ ALL cells. Pre–B cell receptor–medi-
ated cell cycle arrest in Ph+ ALL cells critically depends on IKAROS function, and is reversed 
by coexpression of the dominant-negative IKAROS splice variant IK6. IKAROS also promotes 
tumor suppression through cooperation with downstream molecules of the pre–B cell 
receptor signaling pathway, even if expression of the pre–B cell receptor itself is compro-
mised. In this case, IKAROS redirects oncogenic BCR-ABL1 tyrosine kinase signaling from 
SRC kinase-activation to SLP65, which functions as a critical tumor suppressor downstream 
of the pre–B cell receptor. These findings provide a rationale for the surprisingly high 
frequency of IKAROS deletions in Ph+ ALL and identify IKAROS-mediated cell cycle exit as 
the endpoint of an emerging pathway of pre–B cell receptor–mediated tumor suppression.
© 2009 Trageser et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e1740 IKAROS FUNCTIONS AS TUMOR SUPPRESSOR DOWNSTREAM OF THE PRE–B CELL RECEPTOR | Trageser et al.
cell receptor expression is specific for Ph+ ALL because in a 
group of 54 cases of Ph ALL, including ALL carrying E2A-
PBX1 (n = 8), TEL-AML1 (n = 11), or MYC (n = 4) gene re-
arrangements and ALL with hyperdiploid (n = 18) and normal 
karyotype (n = 13), no evidence for negative selection against 
functional IGHM alleles was found (Fig. 1 A).
Lack of pre–B cell receptor function in Ph+ ALL cells
We next tested whether the pre–B cell receptor is functional 
in the few cases of Ph+ ALL that harbor at least one produc-
tively rearranged IGHM allele. The function of the pre–B cell 
receptor was studied in 7 Ph+ and 10 Ph ALL cell lines. As a 
control, we used bone marrow B cell precursor cells from four 
healthy donors. Engagement of the pre–B cell receptor using 
 chain–specific antibodies resulted in a strong Ca2+ signal   
in normal pre–B cells, but none of the seven Ph+ ALL cases 
(Fig. 1 B). Because normal bone marrow B cell precursors were 
only gated on the pan–B cell antigen CD19, we cannot ex-
clude that IgM+ immature B cells rather than  chain+ pre–B 
cells responded to  chain/IgM engagement. For this reason, 
we also tested 10 Ph ALL cases, 7 of which showed a strong 
Ca2+ signal in response to pre–B cell receptor engagement   
(Fig. 1 B). We conclude that even in the few cases in which a 
 chain can be expressed, the Ph+ ALL cells lack pre–B cell re-
ceptor function, indicating that pre–B cell receptor function is 
compromised in most, if not all, cases of Ph+ ALL.
Down-regulation of pre–B cell receptor–related signaling 
molecules in Ph+ ALL
To investigate expression levels of pre–B cell receptor– 
related signaling molecules in human Ph+ ALL cells, we per-
formed a metaanalysis of published gene expression data of 15 
cases of Ph+ ALL (Ross et al., 2003) and normal human B cell 
precursors (van Zelm et al., 2005), as described in Fig. S2. 
Interestingly, a group of pre–B cell receptor–related genes 
including SYK, SLP65, IGLL1, VPREB1 (surrogate light 
chain), IGHM ( chain), CD79B (Ig signaling chain), and 
IRF4 are consistently down-regulated in Ph+ ALL as com-
pared with normal human B cell precursors (Fig. 1 C, left). 
Analysis of four Ph+ ALL cell lines (BV173, Nalm1, SUP-
B15, and TOM1; Fig. 1 C, middle) that were cultured in the 
presence or absence of STI571 (Imatinib) showed that inhi-
bition of the BCR-ABL1 kinase restored normal messenger 
RNA (mRNA) levels of SYK, SLP65, IGLL1, VPREB1, 
IGHM, and IRF4.
Genomic deletions of pre–B cell receptor–related genes  
in Ph+ ALL
We next studied genomic deletions in the same set of pre–B 
cell receptor–related genes using the 250 NspI SNP-chip plat-
form and found deletions in at least one of these genes in all 
22 Ph+ ALL cases analyzed. We detected VPREB1 and IGLL1 
deletions in 5 of 22 cases and deletions in the SYK, SLP65, 
CD79B, IRF4, and BTLA gene at least once (Fig. 1 C, right). 
With the exception of VPREB1 and IGLL1, all these dele-
tions were heterozygous, so their functional significance 
SLP65 (or BLNK, BASH; Fu et al., 1998; Hayashi et al., 
2000; Fig. S1). In the absence of SLP65, the function of the 
pre–B cell receptor is compromised and SLP65-deficient B 
cell precursors are arrested at the pre–B cell stage (Jumaa et al., 
1999). In virtually all cases, B cell lineage acute lymphoblastic 
leukemia (ALL) is derived from B cell precursors that are ar-
rested at pre–B cell receptor–dependent stages of develop-
ment. Among ALL in adults, the Philadelphia chromosome 
(Ph) encoding the oncogenic BCR-ABL1 tyrosine kinase, 
represents the most frequent cytogenetic abnormality (25–
30% of cases) and defines the ALL subset with the most unfa-
vorable prognosis (Mancini et al., 2005). Ph+ ALL is also 
characterized by deletions of the IKZF1 (IKAROS) gene that 
are found in >80% of Ph+ ALL cases (Mullighan et al., 2008). 
IKZF1 deletions typically lead to the expression of domi-
nant-negative IKAROS variants (e.g., IK6) that are charac-
terized by loss of N-terminal zinc fingers that mediate DNA 
binding, whereas the C-terminal dimerization domain is re-
tained (Klein et al., 2006; Iacobucci et al., 2008; Reynaud et al., 
2008). Based on a previous study of 12 cases of Ph+ ALL, our 
group described inactivation of the pre–B cell receptor in 
Ph+  ALL  based  on  nonfunctional  IGHM  gene  rearrange-
ments (Klein et al., 2004) and down-regulation of pre–B cell 
receptor–related  signaling  molecules  (Klein  et  al.,  2004, 
2006). Here, we confirm these observations based on 57 cases 
of human Ph+ ALL as compared with normal pre–B cells and 
54 cases of Ph ALL and elucidate the mechanism of pre–B 
cell receptor–mediated tumor suppression in Ph+ ALL.
RESULTS
Ph+ ALL clones are selected against expression  
of a functional pre–B cell receptor
To investigate the role of the pre–B cell receptor in Ph+ ALL, 
we studied the configuration of the IGHM locus in sorted 
normal human B cell precursor cells by single-cell PCR, and 
in 54 cases of Ph and 57 cases of Ph+ ALL. The frequency 
of normal human B cell precursors lacking coding capacity 
for a  chain decreased from 41% in pro–B (CD19+ CD34+) 
to 13% in pre–B (CD19+ VpreB+) and to 12% in immature 
B cells (CD10+ CD20+). Because pre–B cell receptor selec-
tion represents an ongoing process, it is possible that some 
CD19+ VpreB+ and CD10+ CD20+ cells were viably sorted 
even though these cells lacked coding capacity for a  chain 
and were therefore destined to die. In addition, in some cells, 
a  second  productively  rearranged  IGHM  allele  may  have 
been missed in our single-cell PCR analysis. Compared with 
random distribution of nonfunctional IGHM alleles (calcu-
lated based on the statistical model described in Table S1), we 
found evidence for positive selection of functional IGHM al-
leles in pre–B cells (P = 0.03) and immature B cells (P = 0.01; 
green asterisks, Fig. 1 A).
In contrast, 47 of 57 (83%) of patient-derived Ph+ ALL 
cases  carried  only  nonfunctional  IGHM  VHDJH  gene  rear-
rangements (Fig. 1 A and Table S1). Ph+ ALL cases are selected 
against expression of a functional IGHM gene rearrangement 
(P = 0.01; red asterisk, Fig. 1 A). Negative selection of pre–B JEM VOL. 206, August 3, 2009 
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IKAROS (Mullighan et al., 2008). Deletions of the VPREB1 
gene encoding part of the pre–B cell receptor surrogate light 
chain were subsequently verified by FISH analysis and quan-
titative genomic PCR (Fig. S3). 3 monoallelic and 2 biallelic 
remains to be investigated. Previous studies showed that   
heterozygous deletions of PAX5 lead to haploinsufficiency 
(Mullighan et al., 2007; Kawamata et al., 2008) and to the ex-
pression of dominant-negative mutants as in the case of 
Figure 1.  Pre-B cell receptor function in normal human B cell precursors and Ph+ ALL. The configuration of the Ig heavy chain (IGHM) locus was 
studied in bone marrow pro–B cells, pre–B cells, immature B cells, 57 cases of Ph+ ALL, and 54 cases of Ph-negative ALL (A). The frequencies of cells/ALL 
clones lacking a functional IGHM gene rearrangement (light bars) and the total frequency of nonfunctional IGHM alleles in these populations (dark bars) 
are shown. The expected frequencies of cells/ ALL clones lacking coding capacity for a pre–B cell receptor based on random distribution (Table S1) are 
indicated as horizontal gray lines. Asterisks denote significant differences from random distribution (P < 0.05). Ca2+ mobilization in response to pre–B cell 
receptor engagement was studied in normal B and pre–B cells, 7 cases of Ph+ ALL and 10 Ph-negative ALL (B). A metaanalysis of published gene expres-
sion data for pre–B cell receptor–related genes in 15 cases of Ph+ ALL and normal human B cell precursors was performed (C, left). P values and false 
discovery rates (FDR) are indicated. Ph+ ALL cell lines (BV173, Nalm1, SUP-B15, and TOM1) were cultured in the presence or absence of 10 mol/STI571 
(Imatinib) for 16 h and analyzed by Affymetrix U133A2.0 microarrays (C, middle). 22 cases of Ph+ ALL were analyzed by a SNP mapping assay (C, right). 
The frequency of deletions is given in percent. The frequencies of deletions in our dataset of 22 cases of Ph+ ALL are plotted against the frequencies of 
deletions found in Ph ALL (Mullighan et al., 2007).1742 IKAROS FUNCTIONS AS TUMOR SUPPRESSOR DOWNSTREAM OF THE PRE–B CELL RECEPTOR | Trageser et al.
(Flemming et al., 2003) or fail to express a  chain because of 
deletion of the C transmembrane domain. In one set of ex-
periments, we reconstituted Slp65 expression in BCR-ABL1–
transformed Slp65/ pre–B ALL cells either constitutively 
(Fig. 3 A) or inducibly (Fig. 3 B; Meixlsperger et al., 2007). 
In both systems, we observed selective depletion of Slp65-
reconstituted BCR-ABL1 ALL cells within 9 d after Slp65 
reconstitution. We also studied one case of primary human 
Ph+ ALL with SLP65 deficiency (Jumaa et al., 2003), recon-
stitution of which had a similar effect (Fig. 3 C).
To investigate the consequences of pre–B cell receptor 
reconstitution  in  vivo,  Slp65/  BCR-ABL1–transformed 
pre–B cells were labeled with lentiviral firefly luciferase and 
transduced  with  Slp65-GFP  or  GFP  alone.  NOD/SCID 
mice  were  sublethally  irradiated  and  injected  with  Slp65-
GFP+ or GFP+ ALL cells. Starting 1 wk after tail vein injection, 
engraftment  was  monitored  by  bioluminescence  imaging 
(Fig. 3 D). As opposed to mice injected with Slp65-GFP–
transduced  leukemia  cells,  the  mice  that  were  inoculated 
with GFP-transduced leukemia cells showed signs of termi-
nal disease and weight loss 36 d after injection. At this time, 
all mice were sacrificed; mice injected with GFP-transduced, 
but not Slp65-GFP–transduced, BCR-ABL1 ALL cells showed 
increased white blood cell counts and expansion of peripheral 
blood B cell precursors (Table S3). Compared with GFP-
transduced leukemia cells, reconstitution of Slp65 expression 
in the Slp65/ BCR-ABL1–transformed pre–B ALL cells 
reduced the leukemia cell burden by 15-fold in the bone 
marrow, 5-fold in the spleen, and >100-fold in the peripheral 
blood (Fig. 3 E and Table S3). We conclude that inactivation 
of the pre–B cell receptor–related signaling molecule Slp65 
not only represents a frequent feature in human ALL cells 
(Jumaa et al., 2003; Fig. 1 C), but also represents a require-
ment for leukemic growth of BCR-ABL1–transformed mouse 
pre–B cells in vivo.
In an alternative approach, we transduced BCR-ABL1–
transformed Ighm/ ALL cells with a retroviral vector en-
coding a functional  chain (Ighm) together with CD8 or 
CD8 alone (control). Enrichment or depletion of /CD8+ 
cells versus CD8+ cells was monitored for 10 d by flow cy-
tometry (Fig. 4 A). We observed progressive loss of /CD8+ 
cells, whereas the population of CD8+ cells remained stable. 
We next reconstituted  chain expression in a primary case 
of human Ph+ ALL, in which both IGHM alleles were non-
productively rearranged. Also in this case, reconstitution of   
 chain expression rapidly suppressed leukemic growth in 
primary human Ph+ ALL cells (Fig. 4 B). We conclude that 
reconstitution of pre–B cell receptor signaling effectively pre-
vents leukemic growth of human Ph+ ALL.
Mechanism of pre–B cell receptor–induced suppression  
of leukemic growth
To clarify how reconstitution of pre–B cell receptor signaling 
in Ph+ ALL cells suppresses leukemic growth, we tested the 
effect of pre–B cell receptor signaling on the survival and 
proliferation of leukemia cells (Fig. 4, C and D, and Fig. 5). 
deletions of the VPREB1 locus were identified in 22 cases of 
Ph+ ALL, but not in any of 22 Ph ALL cases (P < 0.05). We 
conclude that deletions in pre–B cell receptor–related genes 
represent a novel and frequent feature of Ph+ ALL.
Pre–B cell receptor function during leukemic 
transformation in BCR-ABL1 transgenic mice
To investigate the function of the pre–B cell receptor during 
progressive leukemic transformation in vivo, we studied B 
cell precursors in BCR-ABL1 transgenic mice (Heisterkamp 
et al., 1990) at different stages of malignant transformation.   
B cell precursors of (a) wild-type littermates and (b) BCR-ABL1 
transgenic mice at <60 d of age in the absence of any indica-
tion of leukemia (preleukemic), (c) mice with full-blown 
leukemia (>90 d of age) before and (d) after 7 d of treatment 
with the BCR-ABL1 kinase inhibitor AMN107 (Nilotinib; 
Table S2). Interestingly, BCR-ABL1 transgenic pre–B cells 
represent a normal polyclonal population before the onset   
of leukemia, but mainly belong to one single clone in full-
blown leukemia (Fig. 2 A). Treatment with AMN107 erad-
icates the dominant leukemia clone and restores a normal 
polyclonal pre–B cell repertoire. B cell development in BCR-
ABL1 transgenic mice with overt leukemia was arrested at a 
pre–B cell receptor–negative stage of development (Fig. 2 B). 
As opposed to wild-type and preleukemic B cells, B lym-
phoid cells in full-blown leukemia did not express Ig -heavy 
chains (Fig. 2 B). Treatment of the leukemic mice with 
AMN107, however, restored phenotypically normal B cell 
differentiation (Fig. 2 B). Ca2+ release in response to pre–B cell 
receptor engagement was compromised in mice with full-blown 
leukemia, yet restored by treatment of leukemic mice with 
AMN107 (Fig. 2 C).
mRNA  levels  of  pre–B  cell  receptor–related  signaling 
molecules were studied in sorted CD19+ AA4.1+ bone mar-
row pre–B cell populations from wild-type mice and BCR-
ABL1 transgenic mice before and after leukemic transformation 
and after 7 d of treatment with AMN107. Although mRNA 
levels for most pre–B cell receptor–related molecules were 
similar in wild-type and “preleukemic” BCR-ABL1 transgenic 
mice, a subset of these genes (including Ighm, Slp65, and Ikaros) 
was substantially down-regulated upon full leukemic transfor-
mation, as determined by GeneChip analysis (Fig. 2 D) and 
quantitative RT-PCR validation (Fig. 2 E). Together, these 
results suggest that active signaling from a functional pre–B cell 
receptor and the BCR-ABL1 kinase are mutually exclusive.
Reconstitution of pre–B cell receptor signaling in Slp65/ 
and Ighm/ BCR-ABL1–transformed pre–B ALL cells 
suppresses leukemic growth
To test this hypothesis in a formal experiment, we reconsti-
tuted  pre–B  cell  receptor  signaling  in  BCR-ABL1–trans-
formed bone marrow B cell precursors from mice carrying 
pre–B  cell  receptor  defects.  To  this  end,  we  transformed 
bone marrow B cell precursors from Slp65/ and Ighm/ 
mice with retroviral BCR-ABL1 (Fig. 3). These mice lack 
expression of the pre–B cell receptor linker molecule Slp65 JEM VOL. 206, August 3, 2009 
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analysis was gated on  chain/CD8+ and CD8+ cells, which 
underestimates the degree of cell death induction because dy-
ing cells lose  chain/CD8 or CD8 surface expression. In a 
complementary system that allows for inducible activation of 
pre–B cell receptor signaling in all B cell precursors (Hess   
et al., 2001), we further studied the role of pre–B cell recep-
tor signaling in BCR-ABL1 leukemia cells. Such B cell   
To this end, we reconstituted  chain–negative BCR-ABL1 
leukemia cells either with a  chain/CD8 expression vector 
or a CD8 empty vector control and measured cell death in   
 chain/CD8+ and CD8+ cells (Fig. 4, C and D).  Chain 
reconstitution resulted in a modest induction of cell death, 
and most of the leukemia cells remained viable 5 d after re-
constitution (Fig. 4, C and D). It should be noted that this 
Figure 2.  Progressive leukemic transformation of B cell precursors in BCR-ABL1 transgenic mice. B cell precursors from wild-type and  
BCR-ABL1 transgenic mice were analyzed for their clonality using spectratyping of Ig gene rearrangements (A),  chain expression (B), pre–B cell 
receptor responsiveness (C), and gene expression pattern (D), and RT-PCR validation (E; three experiments). Data in A–C are representative of results 
from six independent experiments with at least two mice per group. B cell precursor populations were compared from wild-type animals, preleukemic 
BCR-ABL1 transgenic mice (age <60 d), BCR-ABL1 transgenic mice with full-blown leukemia (age >90 d), and after treatment of mice with AMN107  
(75 mg/kg/d) for 7 d.1744 IKAROS FUNCTIONS AS TUMOR SUPPRESSOR DOWNSTREAM OF THE PRE–B CELL RECEPTOR | Trageser et al.
IKAROS function is required for the ability of the pre–B cell 
receptor to induce cell cycle arrest in Ph+ ALL cells
We then focused our investigation of the mechanism of   
pre–B  cell  receptor–induced  leukemia-suppression  on  the 
IKAROS transcription factor based on the following ratio-
nale. Two recent studies showed that pre–B cell receptor sig-
naling in normal B cell precursors results in up-regulation   
of IKAROS, which subsequently induces cell cycle arrest 
(Thompson et al., 2007; Ma et al., 2008). In addition, a recent 
landmark study demonstrated that deletions of the IKZF1 
(IKAROS) gene represents a defining feature of Ph+ ALL 
(deletions in >80% of the cases; Mullighan et al., 2008). Vali-
dation by quantitative RT-PCR confirmed previous findings 
(Thompson et al., 2007; Ma et al., 2008) that inducible pre–B 
cell receptor activation resulted in a 6–8-fold up-regulation 
of full-length IKAROS mRNA levels within 24 h (Fig. 6 A). 
Within 42 h after induction of pre–B cell receptor expression, 
precursors from Rag2/ tetracycline (Tet)-controlled trans-
activator (tTA)/ chain transgenic mice (Hess et al., 2001) 
were transformed with BCR-ABL1. Rag2/ tTA/ chain 
transgenic B cell precursors are unable to endogenously ex-
press a pre–B cell receptor, but carry a Tet-inducible  chain 
gene (Fig. 5 A). We verified induction of  chain expression 
in Rag2/ tTA/ chain transgenic BCR-ABL1 ALL cells by 
flow cytometry (Fig. 5 A). Because  chain expression in this 
system is regulated by endogenous transcriptional control el-
ements, levels of  chain expression are low, as typically ob-
served in normal pre–B cells (Hess et al., 2001; Fig. 5 A). 
Withdrawal  of Tet  in  BCR-ABL1–transformed  Rag2/ 
tTA/ chain transgenic B cell precursors resulted in  chain 
expression and subsequent suppression of leukemic growth in 
cell culture (Fig. 5, B and C), indicating that the tumor sup-
pressor function of the pre–B cell receptor involves induction 
of cell cycle exit.
Figure 3.  Reconstitution of Slp65 deficiency in BCR-ABL1 ALL cells suppresses leukemic growth BCR-ABL1–transformed Slp65/. ALL cells 
were reconstituted with Slp65/GFP or a GFP empty vector control (A; single measurements in three independent experiments). For inducible Slp65 recon-
stitution, we fused Slp65 to the estrogen receptor ligand-binding domain (ERT2). Either ERT2 fused to the N terminus of Slp65 (ERT2-Slp65/GFP) or ERT2 
alone (ERT2/GFP) were expressed in the Slp65/ BCR-ABL1–transformed ALL cells and activated by addition of 1 mol/l 4-hydroxy-tamoxifen (OHT) 
using ethanol (EtOH) as vehicle control (B; triplicate measurements, the experiment was repeated once). Primary human leukemia cells from one case of 
Ph+ ALL cells lacking expression of SLP65 were cultured on OP9 stroma in the presence of IL-7 and transduced with SLP65/GFP or a GFP empty vector 
control (three independent transductions) and monitored by flow cytometry (C). BCR-ABL1–transformed Slp65/ ALL cells were labeled by lentiviral fire-
fly luciferase, transduced with retroviral vectors encoding either Slp65/GFP or GFP alone and injected into five sublethally irradiated NOD/SCID mice per 
group. Engraftment and leukemic growth was monitored by luciferase-bioimaging (D; experiment repeated once). The blue scale bar in (D) corresponds to 
1 cm in length. Leukemic infiltration (CD19+ GFP+) of bone marrow, spleen, and peripheral blood (three independent experiments) was documented by 
flow cytometry (E; representative data from two experiments).JEM VOL. 206, August 3, 2009 
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IKAROS (Reynaud et al., 2008) and is abundantly expressed in 
most if not all cases of Ph+ ALL (Klein et al., 2006; Iacobucci   
et al., 2008; Mullighan et al., 2008). To test this hypothesis, 
pre–B cell receptor signaling was induced in BCR-ABL1–
transformed Rag2/ tTA/ chain transgenic ALL cells that 
were transduced with the dominant-negative IK6 splice vari-
ant (IK6/GFP) or an empty vector control (GFP; Fig. 6, B–D). 
Whereas IK6/GFP-overexpression did not confer a significant 
close to 70% of viable BCR-ABL1 ALL cells were arrested in 
G0/G1 (Fig. 5, B and C, and Fig. 6, B and C). To investigate 
whether IKAROS function is required for pre–B cell recep-
tor–induced cell cycle arrest, we transduced BCR-ABL1 ALL 
cells with IK6, a dominant-negative splice variant of IKAROS 
(Iacobucci et al., 2008; Klein et al., 2006; Reynaud et al., 
2008). The IK6 splice variant neutralizes IKAROS function 
by forming nonfunctional heterodimers with full-length 
Figure 4.  Reconstitution of  chain expression results in leukemia suppression BCR-ABL1–transformed Ighm/. ALL cells were transduced 
with retroviral expression vectors encoding either CD8 alone or CD8 with a functional  heavy chain. Enrichment or depletion of CD8+ and /CD8+ cells 
was monitored over 10 d (A; three independent transductions). Primary human Ph+ ALL cells lacking coding capacity for expression of a  chain were 
cultured on OP9 stroma in the presence of IL-7 and transduced with  chain/CD8 or CD8 alone and monitored by flow cytometry (B; three independent 
transductions). BCR-ABL1 transgenic mouse B cell lineage leukemia cells lacking  chain expression were transduced with retroviral expression vectors 
encoding either CD8 alone or CD8/ chain (C and D). Percentages of Annexin V+ and propidium iodide+ cells were determined after 2 and 5 d of transduc-
tion and means of three experiments are indicated in (D).1746 IKAROS FUNCTIONS AS TUMOR SUPPRESSOR DOWNSTREAM OF THE PRE–B CELL RECEPTOR | Trageser et al.
deletion leading to expression of dominant-negative IKAROS 
on the other (IKAROS/DN). Whereas IKAROS+/+ Ph+ ALL 
cells are sensitive to pre–B cell receptor reconstitution (SLP65 
and  chain), IKAROS+/DN and IKAROS/DN Ph+ ALL cells 
are largely resistant to pre–B cell receptor–induced leukemia 
suppression (Fig. 7 A). Retroviral expression of the functional 
IKAROS form IK1, however, induced cell cycle arrest in all 
three Ph+ ALL cases (Fig. 7 A), even though leukemia cells in 
none of these cases expressed a functional pre–B cell receptor. 
These findings demonstrate that IKAROS function is required 
for pre–B cell receptor–mediated cell cycle arrest in pre–B cell–
derived Ph+ ALL cells. However, these observations also raise 
the question of how IKAROS can function as a tumor suppres-
sor downstream of the pre–B cell receptor, if pre–B cell receptor 
signaling is inactivated in most, if not all, cases of Ph+ ALL. Al-
though none of the three Ph+ ALL cases studied in Fig. 7 A ex-
press a functional pre–B cell receptor (Fig. 1 B), overexpression 
of the pre–B cell receptor downstream molecule SLP65 was suf-
ficient to induce leukemia suppression, unless IKAROS func-
tion was compromised by genomic deletions (Fig. 7 A).
IKAROS redirects BCR-ABL1-mediated SRC-kinase 
activation to SLP65, a tumor suppressor downstream  
of the pre–B cell receptor
To elucidate how IKAROS intersects signaling from the 
pre–B cell receptor downstream molecules (e.g., SLP65), we 
studied  how  IKAROS  reconstitution  in  IKAROS/pre–B 
growth advantage over GFP background levels in pre–B cell 
receptor–negative BCR-ABL1–transformed ALL cells, pre–B 
cell receptor induction resulted in an up to 25-fold increase 
of IK6/GFP-transduced leukemia cells (Fig. 6 D; a 5-fold in-
crease was measured in one repeat experiment). Previous studies 
demonstrated that IKAROS negatively regulates the G1–S 
phase transition of the cell cycle in pre–B cells (Gómez-del 
Arco et al., 2004; Kathrein et al., 2005), mainly through his-
tone H3 acetylation and up-regulation of negative cell cycle 
regulators, including CDKN1B (Kathrein et al., 2005; Fig. S1). 
Consistent with these findings, we observed that pre–B cell 
receptor/IKAROS-induced cell cycle arrest can be reversed 
by dominant-negative IK6 (Fig. 6, B and C).
IKAROS cooperates with SLP65 as tumor suppressor even  
in the absence of a pre–B cell receptor
If IKAROS function was indeed required for the ability of 
the pre–B cell receptor to induce cell cycle arrest in Ph+ ALL, 
one  would  expect  that  presence  or  absence  of  IKAROS 
(IKZF1) deletions in Ph+ ALL predicts sensitivity of these 
leukemia clones to reconstitution of pre–B cell receptor sig-
naling. We reconstituted pre–B cell receptor signaling (SLP65 
and  chain) in three established human Ph+ ALL clones car-
rying either wild-type IKAROS (IKAROS+/+), a heterozy-
gous deletion leading to the expression of dominant-negative 
IKAROS (IKAROS+/DN), or biallelic deletions of IKAROS 
(large genomic deletion at 7p12 on one allele, and a small   
Figure 5.  Reconstitution of pre–B cell receptor signaling in BCR-ABL1 ALL cells induces cell cycle arrest. Rag2/ tTA/ chain transgenic mice 
are unable to express an endogenous  chain but carry a functionally prerearranged  chain under control of Tet operator (tetO) sequences. These mice 
express a tTA under control of endogenous  chain regulatory elements and withdrawal of Tet results in activation of  chain expression (A; routinely 
performed quality control). The effect of Tet-inducible activation of  chain expression in BCR-ABL1–transformed ALL cells on leukemic growth was mea-
sured in a detailed cell cycle analysis (B-C). Percentages of cells in G0/G1, S and G2/M phases of the cell cycle were calculated and means of three experi-
ments are indicated in C.JEM VOL. 206, August 3, 2009 
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and SLP65; Hendriks and Kersseboom, 2006; Sprangers et al., 
2006). For instance, SRC kinases, but not SYK and SLP65, 
are required for pre–B cell proliferation and NF-B activa-
tion in pre–B cells (Saijo et al., 2003). Likewise, SRC kinase-
driven pre–B cell proliferation is even increased in the absence 
of SLP65 (Flemming et al., 2003). Conversely, pre–B cell 
differentiation depends on SYK/SLP65, but not on SRC ki-
nase signaling (Cheng et al., 1995; Jumaa et al., 1999; Flemming 
et al., 2003). SRC kinase and SYK/SLP65-dependent path-
ways intersect at the level of the ubiquitin ligase CBL. SRC 
kinases, including LYN, activate CBL, which then ubiqui-
tinates SYK for proteasomal degradation (Ota and Samelson, 
1997). Because activation of SLP65 through phosphorylation 
at SLP65-Y96 requires SYK (Fu et al., 1998), SRC kinase/
CBL–induced  degradation  of  SYK  compromises  SLP65- 
mediated pre–B cell differentiation (Song et al., 2007) and tumor 
suppression (Flemming et al., 2003; Hayashi et al., 2003; Fig. S1). 
In Ph+ ALL, LYN, HCK, FGR, BTK, and CBL are all tyro-
sine-phosphorylated by BCR-ABL1, but not SYK and SLP65 
(Hu et al., 2004; Ptasznik et al., 2004; Feldhahn et al., 2005; 
Fig. 7 B). Whereas the SRC kinase pathway is critical for the 
survival of Ph+ ALL cells (Hu et al., 2004; Ptasznik et al., 
cell receptor double-deficient leukemia cells affects the activity 
of pre–B cell receptor downstream molecules (Fig. 7 B). Un-
like other subtypes of ALL, Ph+ ALL is driven by a constitu-
tively active tyrosine kinase that is encoded by the BCR-ABL1 
oncogene. Therefore, tyrosine phosphorylation of pre–B cell 
receptor downstream molecules in Ph+ ALL is not necessarily 
initiated from the pre–B cell receptor and may also originate 
from the oncogenic BCR-ABL1 kinase. Indeed, the onco-
genic BCR-ABL1 tyrosine kinase in Ph+ ALL phosphorylates 
downstream signaling components of the pre–B cell receptor, 
thereby mimicking survival and proliferation signals from the 
pre–B cell receptor (Feldhahn et al., 2005).
As  shown  by  us  and  others,  the  pre–B  cell  receptor– 
related molecules LYN (Hu et al., 2004; Ptasznik et al., 2004), 
HCK, FGR (Hu et al., 2004), BTK (Bäckesjö et al., 2002; 
Feldhahn et al., 2005), and CBL (Sattler et al., 2002) are all 
tyrosine phosphorylated by BCR-ABL1. These molecules 
belong to the SRC kinase pathway downstream of the pre–B 
cell receptor, which mainly promotes survival and prolifera-
tion through activation of NF-B (Saijo et al., 2003; Hendriks 
and Kersseboom, 2006). SRC kinase signaling is distinct from 
proximal pre–B cell receptor signaling components (e.g., SYK 
Figure 6.  Pre-B cell receptor–mediated suppression of leukemic growth requires IKAROS function. mRNA levels of Ikaros after  chain induc-
tion were measured by quantitative RT-PCR (A; three experiments). BCR-ABL1–transformed ALL cells were retrovirally transduced with the dominant-
negative IKAROS splice variant IK6/GFP or a GFP empty vector control (B–D). Leukemia cells transduced with IK6/GFP (+IK6) or an empty vector control 
(-IK6) were studied in the presence or absence of pre–B cell receptor activation (+/  chain). IK6/GFP- and GFP-transduced leukemia cells were sub-
jected to cell cycle analysis in the presence or absence of inducible pre–B cell receptor signaling (B–D). The percentages of cells in G0/G1, S and G2/M 
phase are indicated and means of three experiments are indicated in C. In D, the relative increase or decrease of IK6/GFP+ versus GFP+ leukemia cells in 
the presence or absence of pre–B cell receptor activation (±  chain) was measured. The experiment was repeated once.1748 IKAROS FUNCTIONS AS TUMOR SUPPRESSOR DOWNSTREAM OF THE PRE–B CELL RECEPTOR | Trageser et al.
DT40 B cell lymphoma, reconstitution of IKAROS rein-
states SYK/SLP65 signaling and dephosphorylates LYN/CBL 
(Nera et al., 2006). For this reason, we examined whether 
IKAROS can play a similar role in Ph+ ALL, where BCR-
ABL1 phosphorylates LYN, CBL and other molecules of the 
SRC kinase pathway (Hu et al., 2004; Ptasznik et al., 2004; 
Feldhahn et al., 2005), but not SYK and the tumor suppres-
sor SLP65 (Feldhahn et al., 2005 and Fig. 7 B). To this end, 
we studied the effect of IKAROS-reconstitution on protein 
expression and tyrosine phosphorylation of LYN/CBL and 
2004), SYK and SLP65 are frequently down-regulated and 
occasionally deleted in Ph+ ALL (Fig. 1 C), and SLP65 functions 
as a potent tumor suppressor downstream of the pre–B cell 
receptor (Fig. 3, 7A).
Notably,  a  recent  study  demonstrated  the  ability  of 
IKAROS to redirect B cell receptor signaling in DT40 B cell 
lymphoma from preferential tyrosine phosphorylation of LYN/
CBL to SYK/SLP65 (Nera et al., 2006). Whereas LYN/CBL 
(at the expense of SYK/SLP65) are the main substrates of B 
cell receptor–induced phosphorylation in IKAROS-deficient 
Figure 7.  Reconstitution of IKAROS expression in Ph+ ALL cells results in BCR-ABL1-mediated activation of SLP65 even in the absence of a 
pre–B cell receptor. Genotype and expression of IGHM ( chain), SLP65, and IKAROS (both functional IK1 and dominant-negative IK6 forms of IKAROS) 
were studied in three cases of Ph+ ALL. Ph+ ALL cells were transduced once in each case with retroviral vectors encoding SLP65/GFP, IKAROS (IK1)/GFP and 
 chain/CD8 or GFP- and CD8-empty vector controls. Enrichment or depletion of GFP+ and CD8+ cells was monitored by flow cytometry (A; three cases 
were studied). IKAROS-deficient leukemia cells from Ph+ ALL cases 1 and 2 were transduced with a retroviral expression vector for IKAROS (IK1)/GFP and a 
GFP empty vector control. 2 d after transduction, GFP+ cells were sorted and cultured in the presence or absence of 10 mol/liter Imatinib for 12 h (B). 
Protein lysates from these cells were then subjected to Western blot analysis using antibodies against the SRC family kinase LYN, activated SRC kinases 
(including LYN) that are phosphorylated at Y416, the ubiquitin-ligase CBL, activated CBL phosphorylated at Y731, SLP65, and activated SLP65 phosphory-
lated at Y96. Antibodies against EIF4E were used as a loading control. Experiments on two cases were performed. In (C), pre–B cells isolated from bone 
marrow of Slp65/ mice were transformed by a retrovirus encoding BCR-ABL1/Neo. In three experiments, BCR-ABL1–transformed Slp65/ ALL cells 
were reconstituted with retroviral expression vectors encoding wild-type SLP65/GFP or the mutant SLP65Y96F/GFP or transduced with a GFP empty vec-
tor control (C).JEM VOL. 206, August 3, 2009 
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SLP65 (Fig. 7 B), a critical tumor suppressor downstream of 
the pre–B cell receptor. We propose that even in the absence 
of a functional  chain, IKAROS functions as a tumor sup-
pressor in Ph+ ALL through its ability to divert oncogenic 
BCR-ABL1 kinase signaling to the pre–B cell receptor down-
stream  linker  molecule  SLP65.  According  to  this  scenario, 
SLP65 is at the center of an IKAROS-dependent pathway of 
tumor suppression in Ph+ ALL (Fig. S1). Activation of SLP65 
(phosphorylation at Y96) is either initiated from the pre–B cell 
receptor ( chain, SYK; Fig. S1 A) or through IKAROS- 
mediated diversion of BCR-ABL1, when pre–B cell receptor 
signaling is compromised (Fig. S1 B). In both cases, SLP65, 
when  phosphorylated  at  Y96  would  inhibit  STAT5–JAK3   
signaling (Nakayama et al., 2009) and induce cell cycle arrest 
through up-regulation of IKAROS (Fig. 6) and p27 (CDKN1B; 
Gómez-del Arco et al., 2004; Kathrein et al., 2005). If both 
pre–B cell receptor and IKAROS signaling are compromised, 
however,  this  pathway  of  tumor  suppression  is  inactivated   
(Fig. S1 C). In this case, SLP65 is no longer activated down-
stream of the pre–B cell receptor or through IKAROS-mediated 
rerouting of BCR-ABL1  kinase  activity.  Instead,  BCR-
ABL1 activates SRC kinases (LYN, HCK, and FGR; Hu et al., 
2004; Ptasznik et al., 2004), BTK (Feldhahn et al., 2005) and 
STAT5–JAK3 (Ilaria and Van Etten., 1996), which promote 
oncogenic survival signaling (Ilaria and Van Etten, 1996; 
Hu et al., 2004; Ptasznik et al., 2004; Feldhahn et al., 2005). 
In addition, BCR-ABL1–mediated phosphorylation of LYN 
leads to activation of CBL, which ubiquitinates SYK for pro-
teasomal degradation (Ota and Samelson, 1997; Fig. S1C).   
Because SYK kinase activity is required for activation of 
SLP65 (phosphorylation of SLP65-Y96; Fu et al., 1998), 
BCR-ABL1/LYN/CBL-induced  proteasomal  degradation 
of SYK also prevents further activation of the SLP65 tumor 
suppressor (Fig. S1 C). As a consequence, SRC kinase sig-
naling downstream of BCR-ABL1 induces survival signaling 
through activation of NF-B (Saijo et al., 2003; Fig. S1 C), 
whereas  BCR-ABL1–mediated  activation  of  STAT5–JAK3 
induces proliferation via up-regulation of MYC (Tsuruyama   
et al., 2002; Fig. S1 C). Although our findings do not exclude 
other important functions of the IKAROS tumor suppressor 
in Ph+ ALL, we propose that IKAROS induces cell cycle ar-
rest downstream of the pre–B cell receptor and also reroutes 
oncogenic BCR-ABL1 kinase activity into the pre–B cell re-
ceptor signaling pathway, even if signaling from the  chain is 
compromised. Future experiments will focus on the mecha-
nism through which IKAROS diverts BCR-ABL1 kinase ac-
tivity from the SRC kinase pathway (survival, proliferation) to 
SYK/SLP65 (differentiation, cell cycle control).
MATERIALS AND METHODS
Patient samples, human cells, and cell lines. Normal human pro–B 
cells (CD19+ CD34+ VpreB-), pre–B cells (CD19+ CD34 VpreB+) and im-
mature B cells (CD19+ CD10+ CD20+) were sorted from human bone mar-
row  (from  four  healthy  donors;  Cambrex,  Verviers,  Belgium)  by  flow 
cytometry using antibodies from BD and a FACSVantage SE cell sorter (BD). 
Single cells from each population were sorted into PCR reaction tubes for 
single-cell PCR analysis of Ig VH-DJH gene rearrangements.
SLP65 in two IKAROS-/ chain double-deficient Ph+ ALL 
cases (Fig. 7 B). IKAROS reconstitution (IK1) had no signif-
icant effect on global protein levels of LYN, CBL, and SLP65. 
However, tyrosine phosphorylation of SRC family kinases 
(including LYN) at Y416 and CBL at Y731 was substantially 
reduced upon IKAROS reconstitution, as previously observed 
in DT40 chicken B cells. In contrast, IKAROS reconstitu-
tion resulted in de novo tyrosine phosphorylation of the tu-
mor suppressor SLP65 at Y96. This phosphorylation event 
was sensitive to BCR-ABL1 kinase inhibition by Imatinib 
(Fig. 7 B), suggesting that oncogenic BCR-ABL1 kinase ac-
tivity is indeed redirected to SLP65-Y96. Importantly, a re-
cent study demonstrated that Y96 of SLP65 is crucial for the 
ability of SLP65 to bind and, hence, inhibit JAK3–STAT5 
(Nakayama et al., 2009), a pathway that is also activated in 
oncogenic BCR-ABL1 signaling (Danial et al., 1995). Inhi-
bition of JAK3–STAT5 signaling through interaction with 
SLP65 Y96 leads to activation of p27 (CDKN1B) and rapid 
cell cycle arrest (Nakayama et al., 2009). Consistent with a 
tumor suppressor pathway that requires interaction of SLP65-
Y96 with JAK3–STAT5 proteins, we observed that SLP65-
Y96F,  in  contrast  to  wild-type  SLP65,  failed  to  suppress 
BCR-ABL1–driven leukemic growth (Fig. 7 C).
DISCUSSION
Previous work by our group showed that leukemia cells in 
Ph+ ALL often lack coding capacity for a pre–B cell receptor 
(Klein et al., 2004) and down-regulate pre–B cell receptor–
related signaling molecules (Klein et al., 2004; Klein et al., 
2006). These findings suggested that leukemia clones in Ph+ 
ALL either bypass pre–B cell receptor selection or are even 
selected against expression of a pre–B cell receptor.
Here, we demonstrate that pre–B cell receptor signaling 
suppresses proliferation of Ph+ ALL cells via up-regulation of 
IKAROS and IKAROS-mediated cell cycle arrest (Fig. 5). 
Specifically, upstream components of the pre–B cell receptor 
signaling complex, including the  chain (Fig. 4) and SLP65 
(Fig. 3), function as potent tumor suppressors and induce cell 
cycle exit through an IKAROS-dependent mechanism (Fig. 6 
and Fig. 7). Consistent with a tumor suppressor role of the 
pre–B cell receptor, its function is compromised in most if not 
all cases of Ph+ ALL (Fig. 1). This raises the question how 
IKAROS can function as a tumor suppressor downstream of 
the pre–B cell receptor, if  chain expression is compromised 
in most, if not all, cases of Ph+ ALL. In this respect, Ph+ ALL 
differs from other subtypes of ALL by its particularly high fre-
quency of IKAROS deletions (>80%, Mullighan et al., 2008) 
and by the fact that Ph+ ALL is driven by a constitutively active 
tyrosine kinase (BCR-ABL1) that activates critical signaling 
molecules (SRC kinases, BTK, and CBL) downstream of the 
pre–B cell receptor (Hu et al., 2004; Ptasznik et al., 2004; 
Feldhahn et al., 2005). Here, we show that these two charac-
teristics of Ph+ ALL are linked to each other because pre–B cell 
receptor signaling induced up-regulation of IKAROS (Fig. 6) 
and  reconstitution  of  IKAROS  redirects  oncogenic  BCR-
ABL1 tyrosine kinase signaling from SRC kinase activation to 1750 IKAROS FUNCTIONS AS TUMOR SUPPRESSOR DOWNSTREAM OF THE PRE–B CELL RECEPTOR | Trageser et al.
map with Java TreeView. Cel files from GeneChip arrays are available from 
GEO under accession no. GSE7182 and were imported to the BRB Array 
Tool (http://linus.nci.nih.gov/BRB-ArrayTools.html) and processed using 
the RMA algorithm (Robust Multi-Array Average) for normalization and 
summarization. Affymetrix U133A2.0 GeneChip data from four human Ph+ 
ALL cell lines (BV173, Nalm1, SUP-B15, and TOM1) generated by us are 
accessible through GEO accession GSE7182.
Quantitative RT-PCR analysis. For quantitative RT-PCR analysis of 
human BCR-ABL1, mouse Hprt, Slp65, Ighm, and Ikaros, PCR primers are 
listed in Table S4. Quantitative real-time PCR performed with the SYBR 
GreenER mix (Invitrogen) was performed according to standard PCR con-
ditions and an ABI7900HT (Applied Biosystems) real-time PCR system.
BCR-ABL1 kinase inhibitors STI571 and AMN107. STI571 and AMN107 
were obtained from Novartis Pharmaceuticals. Leukemic BCR-ABL1 trans-
genic mice were fed a mixture of 8 parts peanut butter and 2 parts vegetable oil, 
with 75 mg of AMN107/kg body weight added to the same peanut/oil mixture 
daily. After 7 d of treatment, mice were sacrificed and leukemia cells were ana-
lyzed in the peripheral blood, bone marrow, and spleen.
BCR-ABL1 transgenic mice. The BCR-ABL1 transgenic mouse model 
was described previously (Heisterkamp et al., 1990). In the C57BL/6J back-
ground, mean age at death for the f10-f15 generation (n = 127) was 100 d 
(range, 38–265 d). In the experiments described here, healthy and pheno-
typically normal BCR-ABL1 transgenic mice at an age <60 d were consid-
ered preleukemic.
Slp65/ mice. Targeting of the Slp65 locus in BALB/c mice resulted in 
replacement of the Slp65 exon 4 by a Neomycin selection cassette in oppo-
site transcriptional orientation (Jumaa et al., 1999). These mice lack expres-
sion of functional Slp65, but exhibit Neo-Slp65 fusion transcripts. Bone 
marrow–derived B cells from these mice are arrested at the pre–B cell stage 
of development and proliferated vigorously under cell culture conditions in 
the presence of 10 ng/ml mouse IL-7.
Ighm/ mice. The transmembrane domain of the constant  region was 
targeted in these mice (The Jackson Laboratory). B cell precursors in these 
mice can undergo V(D)J recombination of Ig variable genes, but they fail to 
express a  chain on the cell surface and therefore lack pre–B cell receptor 
function. B cell precursors in Ighm/ mice are arrested at the pro–B cell stage 
of development. Bone marrow from Ighm/ mice was isolated and B cell 
precursors were propagated in the presence of 10 ng/ml mouse IL-7.
Rag2/ tTA/ chain transgenic mice. Rag2/ tTA/ chain transgenic 
mice (Hess et al., 2001) are unable to express an endogenous  chain because 
they lack Rag2-dependent V(D)J recombination, but carry a functionally 
prerearranged  chain under control of Tet operator sequences in the germ-
line. In addition, Rag2/ tTA/ chain transgenic mice express a tTA under 
control of endogenous  chain regulatory elements.
Reconstitution of pre–B cell receptor defects in Ph+ ALL and 
BCR-ABL1–transformed mouse ALL cells. Human Ph+ ALL cells 
lacking  chain, SLP65 or IKAROS expression were transduced with ret-
roviral vectors (MSCV backbone described in Pear et al., 1998) encoding 
a functional  chain/CD8, the active IKAROS form IK1/GFP or SLP65/
GFP. CD8 and GFP empty vector controls were used. Bone marrow cells 
from Rag2/ tTA/ chain transgenic, Ighm/, and Slp65/ mice were 
transduced with retroviral vectors encoding p190 and p210 BCR-ABL1 
(Pear et al., 1998) in the presence of 10 ng/ml IL-7, which results in the 
outgrowth of pre–B ALL (Li et al., 1999). After transformation, IL-7 was 
no longer supplemented. Ighm/ ALL cells were transduced with retro-
viral constructs encoding mouse CD8 alone or CD8 and a functional 
mouse  chain. In a different set of experiments, Slp65/ ALL cells were 
VH-DJH gene rearrangements were analyzed from 111 ALL cases, in-
cluding 57 cases of Ph+ ALL and 54 cases of Ph-negative ALL. For 82 ALL 
cases, we amplified and sequenced clonal VH-DJH gene rearrangements from 
leukemia-derived cDNA, and for 9 cases, we reanalyzed primary data pro-
vided by M.J.S. Dyer (Institute of Cancer Research, Sutton, England, UK). 
For 10 additional cases of Ph+ ALL, sequence data from EMBL/GenBank/
DDBJ (M.J. Brisco, Flinders University, Adelaide, Australia; accession nos. 
L77971.1, L77974.1, L77980.1, L77982.1–L77987.1, L77989.1) were reana-
lyzed. Fresh leukemic blasts were isolated from patient-derived bone marrow 
samples with Ph+ ALL. Primary leukemia cells were cultured on OP9 stroma 
cells in the presence of 10 ng/ml human IL-7. Patient samples were provided 
from the Departments of Hematology and Oncology, University Hospital 
Benjamin Franklin, Berlin, Germany (W.K. Hoffman), the University of 
Bologna, Bologna, Italy (G. Martinelli), and the Department of Medical Bio-
sciences, Pathology, Umea University, Umea, Sweden (A. Li) and the USC 
Norris Comprehensive Cancer Center in compliance with Institutional Re-
view Board regulations (approval from the Ethik-Kommission of the Charité, 
Campus Benjamin Franklin and the Internal Review Board of the University 
of Southern California Health Sciences Campus). The human ALL cell lines 
380, 697, BV173, Kasumi-2, MHH-Call3, Nalm1, Nalm6, RCH-ACV, 
SD1, SEM, SUP-B15, and TOM1 were purchased from DSMZ.
Single-cell PCR and sequence analysis of VH-DJH gene rearrange-
ments. Single pro–, pre–, and immature B cells were FACS sorted into indi-
vidual PCR reaction tubes containing 20 µl 1X PCR reaction buffer. Single 
cells were then digested using proteinase K and subjected to a whole-genome 
preamplification step, as previously described (Müschen et al., 2000). Aliquots 
from these reactions were used for two rounds of PCR amplification using the 
primer sets detailed in Table S4 in 35 and 45 cycles, respectively.
SNP mapping assay for genomic deletions. Genomic DNA was ex-
tracted from 22 bone marrow Ph+ ALL samples, in which blast counts were 
>80%, using the DNA Blood Mini kit (QIAGEN) and quantified using a 
NanoDrop Spectrophotometer. The SNP mapping assay (Affymetrix) started 
with the digestion of 250 ng of DNA sample (NspI), followed by ligation of a 
common primer and amplification by PCR. The PCR conditions were opti-
mized for the selective amplification of fragments that are 250–2,000 nt in 
length. The amplicons were fragmented by DNaseI digestion and labeled us-
ing TdT and a biotinylated nucleotide analogue, and then hybridized to 250K 
NspI arrays (Affymetrix). After washing and staining, the arrays were scanned 
for data analysis using the GeneChip Scanner 3000 (Affymetrix). CEL files 
were generated using GeneChip Genotyping Analysis Software (GTYPE) 
version 4.0. SNP calls were generated using GTYPE. Affymetrix CEL files 
were analyzed for genomic copy number variations using Partek Genomic 
Suite V and are available from GEO under accession no. GSE13612. The un-
derlying algorithm of CNAG strongly improves the signal-to-noise ratios of 
the final copy number output by correcting for length and GC content of the 
individual PCR products using quadratic regressions and by providing fully 
automated optimal sample selection. Copy number aberrations were scored 
using the Hidden Markow Model and by visual inspection. All aberrations 
were calculated with respect to a set of 48 HapMap normal individuals.
Affymetrix GeneChip analysis. CD19+ AA4.1+ bone marrow B cell pre-
cursors were FACS sorted from each three wild-type, BCR-ABL1 trans-
genic, preleukemic mice with full-blown ALL and from leukemic mice after 
7 d of treatment with the BCR-ABL1 kinase inhibitor AMN107. Total 
RNA from cells used for microarray or RT-PCR analysis was isolated by 
RNeasy (QIAGEN) purification. Double-strand complementary DNA was 
generated from 5 µg of total RNA using a poly(dT) oligonucleotide that 
contains a T7 RNA polymerase initiation site and the SuperScript III reverse 
transcription  (Invitrogen).  Biotinylated  cRNA  was  generated  and  frag-
mented according to the Affymetrix protocol and hybridized to 430 mouse 
microarrays (Affymetrix). To determine relative signal intensities, the ratio of 
intensity for each sample in a probeset was calculated by normalizing to the 
mean value. Ratios were exported in Gene Cluster and visualized as a heat JEM VOL. 206, August 3, 2009 
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Western blot. Polyclonal antibodies against LYN, SRC phospho-Y416, 
CBL, CBL phospho-Y731, SLP65, SLP65 phospho-Y96, and a monoclonal 
antibody against EIF4E (C46H6) were purchased from Cell Signaling Tech-
nologies. Western blot analysis was performed using the Western breeze kit 
(Invitrogen). Imatinib (Gleevec, STI571) was a gift from Novartis.
Measurement of Ca2+ release in response to pre–B cell receptor en-
gagement. CD19+ cells from peripheral blood and bone marrow of healthy 
donors were purified using immunomagnetic beads (Miltenyi Biotech).   
Human and mouse B cell and ALL populations were treated with antibodies 
specific for the  chain of human (Jackson ImmunoResearch Laboratories) 
and mouse (SouthernBiotech) origin. Ca2+ release from cytoplasmic stores in 
response to (pre–) B cell receptor engagement was measured by loading of 
the cells with the lipophilic Fluo-4 dye (Invitrogen).
Online supplemental material. Table S1 presents the amino acid transla-
tion of the IGHM VDJ junction sequence of single sorted pro– and pre–B 
cells and immature B cells from healthy donors (A) and 57 cases of Ph+ ALL 
(B). Table S1 also includes a description of our statistical model for the com-
parison of functional versus nonfunctional IGHM V-DJ gene rearrangements. 
Table S2 presents data on white blood counts, counts of peripheral blood B cell 
precursors, and splenic weights in BCR-ABL1 transgenic mice during pro-
gressive transformation. Table S3 presents data on white blood counts, counts 
of peripheral blood B cell precursors, and splenic weights in a different mouse 
model, in which NOD/SCID mice were injected with SLP65/ pre–B cells 
that were transformed by retroviral BCR-ABL1. Table S4 presents a sum-
mary of oligonucleotides used for single-cell PCR, quantitative RT-PCR 
and Ig spectratyping. Fig. S1 presents a schematic rendition of our scenario 
for the cooperation between pre–B cell receptor signaling and IKAROS as 
tumor suppressors in Ph+ ALL. Fig. S2 presents details of our normalization 
algorithm and comparison of two previously published microarray analyses 
(Ross et al., 2003; van Zelm et al., 2005) in one meta-analysis (Fig. 1 C). Fig. S3 
shows experimental data on verification of VPREB1 gene deletions in Ph+ 
ALL by FISH and genomic quantitative PCR. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20090004/DC1.
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